The company announced the acquisition of 100% global ownership of its novel antibiotic Enmetazobactam, which was originally discovered and developed in-house.
The company announced the acquisition of 100% global ownership of its novel antibiotic Enmetazobactam, which was originally discovered and developed in-house.